—
C+
C+ The full Closelook — membership. Open the C+ overview

Bausch + Lomb Corp (BLCO) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Bausch + Lomb Corp

BLCO in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Bausch + Lomb operates as an eye health company, selling across three segments: Vision Care, Pharmaceuticals and Surgical. Vision Care covers contact lenses, lens-care products, vitamins and over-the-counter eye drops. Pharmaceuticals covers treatments for glaucoma, inflammation, dry eye and retinal disease. Surgical covers cataract, corneal, vitreous and retinal devices, including intraocular lenses and phacoemulsification equipment. It sells through direct sales forces and distributors, is headquartered in Vaughan, Canada, and operates as a subsidiary of Bausch Health Companies.
Where it sits in the stack
Bausch + Lomb holds no seat in Rubin, our AI build-out index; it sits in our broader universe under healthcare, in the medical instruments and supplies sector.
Who it is priced against
No peer group is set for this name in our coverage; the comparison the market draws is with Alcon, another eye-care company spanning vision care, pharmaceuticals and surgical devices.
Why Closelook tracks it
Bausch + Lomb holds no seat in Rubin or our other indices, and it carries no Closelook score; coverage here rests on price and chart structure alone.
What the diary watches
Whether the segment mix shifts, as the diary watches whether Surgical grows relative to Vision Care and Pharmaceuticals, and whether the recent chart pullback continues or steadies.

Bausch + Lomb Corp (BLCO) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 35/100 composite (momentum 56, quality 27, valuation 52) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for BLCO, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Healthcare · US · 8 names with week and year-to-date

Peer group

Healthcare · US

Scored names in the same sector and country from the Closelook universe.

Compared against BLCO on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sector × region Health care in US: +0.7% week · +0.4% month · +10.2% quarter · +6.7% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-16
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Bausch + Lomb Corp (BLCO)?

Bausch + Lomb Corp trades as BLCO on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-18.

Is BLCO in a Closelook index?

Not currently — Bausch + Lomb Corp is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

What is Bausch + Lomb Corp's Closelook composite score?

35 out of 100, with momentum 56, quality 27 and valuation 52 sub-scores, as of 2026-09-18. Scores are Closelook's own research readings, not ratings or investment advice.

Where does BLCO trade against its moving averages?

Pullback inside an uptrend stack: Trades -0.9% vs the 50-day and +0.8% vs the 200-day average, 11.3% below the 52-week high and +21.8% off the 52-week low; a golden cross printed 15 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Bausch + Lomb Corp do?

Bausch + Lomb operates as an eye health company, selling across three segments: Vision Care, Pharmaceuticals and Surgical. Vision Care covers contact lenses, lens-care products, vitamins and over-the-counter eye drops. Pharmaceuticals covers treatments for glaucoma, inflammation, dry eye and retinal disease. No peer group is set for this name in our coverage; the comparison the market draws is with Alcon, another eye-care company spanning vision care, pharmaceuticals and surgical devices.

Where does Bausch + Lomb Corp sit in the AI build-out?

Bausch + Lomb holds no seat in Rubin, our AI build-out index; it sits in our broader universe under healthcare, in the medical instruments and supplies sector. Bausch + Lomb holds no seat in Rubin or our other indices, and it carries no Closelook score; coverage here rests on price and chart structure alone.

What does this page show?

A live price chart with SMA overlays and drawing tools for BLCO, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe